Cargando…
Specification of drug substances and products : development and validation of analytical methods /
Specification of Drug Substances and Products: Development and Validation of Analytical Methods is a comprehensive and critical analysis of the requirements and approaches to setting specifications for new pharmaceutical products, with an emphasis on phase-appropriate development and validation of a...
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | , , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Amsterdam :
Elsevier,
[2014]
|
| Colección: | Progress in pharmaceutical and biomedical analysis.
|
| Temas: | |
| Acceso en línea: | Texto completo |
MARC
| LEADER | 00000cam a2200000 i 4500 | ||
|---|---|---|---|
| 001 | SCIDIR_ocn861537317 | ||
| 003 | OCoLC | ||
| 005 | 20231117044926.0 | ||
| 006 | m o d | ||
| 007 | cr cn||||||||| | ||
| 008 | 131008t20142014ne a ob 001 0 eng d | ||
| 040 | |a E7B |b eng |e rda |e pn |c E7B |d N$T |d OPELS |d YDXCP |d OCLCF |d GGVRL |d UWO |d EBLCP |d UKDOC |d OCLCQ |d USU |d OCLCO |d ICA |d OCLCA |d OCLCO |d LVT |d OCLCQ |d COCUF |d AGLDB |d K6U |d PIFAG |d FVL |d ZCU |d OCLCO |d MERUC |d OCLCO |d SAV |d OCLCO |d U3W |d OCLCA |d STF |d D6H |d OCLCQ |d VTS |d VT2 |d OCLCQ |d WYU |d OCLCO |d TKN |d DKC |d OCLCO |d OCLCQ |d M8D |d OCLCQ |d OCLCA |d AJS |d OCLCO |d OCLCQ |d OCLCO | ||
| 015 | |a GBB358820 |2 bnb | ||
| 016 | 7 | |a 016448212 |2 Uk | |
| 019 | |a 863821936 |a 880437636 |a 1055393858 |a 1065703744 |a 1071485121 |a 1081234603 | ||
| 020 | |a 9780080983431 |q (electronic bk.) | ||
| 020 | |a 008098343X |q (electronic bk.) | ||
| 020 | |z 9780080983509 | ||
| 020 | |z 0080983502 |q (hbk.) | ||
| 035 | |a (OCoLC)861537317 |z (OCoLC)863821936 |z (OCoLC)880437636 |z (OCoLC)1055393858 |z (OCoLC)1065703744 |z (OCoLC)1071485121 |z (OCoLC)1081234603 | ||
| 050 | 4 | |a RS189 |b .S64 2014eb | |
| 060 | 4 | |a QV 771 | |
| 072 | 7 | |a MED |x 071000 |2 bisacsh | |
| 082 | 0 | 4 | |a 615.19 |
| 245 | 0 | 0 | |a Specification of drug substances and products : |b development and validation of analytical methods / |c edited by Christopher M. Riley, Riley and Rabel Consulting Services, Maryville, MO, USA, Thomas W. Rosanske, T.W. Rosanske Consulting, Overland Park, KS, USA, Shelley R, Rabel Riley, Department of Natural Sciences, Northwest Missouri State University, Maryville, MO, USA ; Riley and Rabel Consulting Services, Maryville, MO, USA. |
| 264 | 1 | |a Amsterdam : |b Elsevier, |c [2014] | |
| 264 | 4 | |c �2014 | |
| 300 | |a 1 online resource (389 pages) : |b illustrations | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 1 | |a Progress in Pharmaceutical and Biomedical Analysis | |
| 504 | |a Includes bibliographical references and index. | ||
| 505 | 0 | |a Part 1. Introduction -- part 2. Universal tests -- part 3. Specific tests : drug substance -- part 4. Specific tests : drug product -- part 5. Pharmacopeial methods -- part 6. Microbial methods -- part 7. Biological fluids. | |
| 588 | 0 | |a Online resource; title from PDF title page (ebrary, viewed October 8, 2013). | |
| 520 | |a Specification of Drug Substances and Products: Development and Validation of Analytical Methods is a comprehensive and critical analysis of the requirements and approaches to setting specifications for new pharmaceutical products, with an emphasis on phase-appropriate development and validation of analytical methods. This book is intended as more than a review of new regional guidelines, existing regulatory guidance, and industry practices. It provides a hands-on guide to understanding and applying these in practice. The authors discuss critical issues, novel approaches, and future directions while also providing insight into how International Guidelines were developed and the rationale behind them. Guide to industry best practices of analytical methodologies used in the specification of new drug substances and products (e.g. DOE, QbD)Critical assessment of the application of ICH guidelines on method validation and specification setting, written by experts involved in the development and application of the guidelines to aid understanding of requirements and what is expected by regulatory authoritiesDirect applicability to the day-to-day activities in drug development and the potential to increase productivity. | ||
| 650 | 0 | |a Drugs |x Analysis |x Methodology. | |
| 650 | 2 | |a Pharmaceutical Preparations |x methods | |
| 650 | 2 | |a Pharmaceutical Preparations |x standards |0 (DNLM)D004364Q000592 | |
| 650 | 6 | |a M�edicaments |0 (CaQQLa)201-0036381 |x Analyse |0 (CaQQLa)201-0036381 |x M�ethodologie. |0 (CaQQLa)201-0379663 | |
| 650 | 7 | |a MEDICAL |x Pharmacology. |2 bisacsh | |
| 650 | 7 | |a Drugs |x Analysis |x Methodology |2 fast |0 (OCoLC)fst00898771 | |
| 700 | 1 | |a Riley, Christopher M. | |
| 700 | 1 | |a Rosanske, Thomas W. | |
| 700 | 1 | |a Riley, Shelley R. Rabel. | |
| 776 | 0 | 8 | |i Print version: |t Specification of drug substances and products. |d Amsterdam : Elsevier, 2014 |z 9780080983509 |w (DLC) 2013444132 |
| 830 | 0 | |a Progress in pharmaceutical and biomedical analysis. | |
| 856 | 4 | 0 | |u https://sciencedirect.uam.elogim.com/science/book/9780080983509 |z Texto completo |